PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1887156
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1887156
Prostate Cancer Hormone Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of prostate cancer hormone therapy Market
The global prostate cancer hormone therapy market is witnessing robust growth as prostate cancer prevalence continues to rise and treatment innovations advance rapidly. According to the latest industry estimates, the market was valued at USD 16.07 billion in 2024, is expected to reach USD 20.44 billion in 2025, and is projected to surge to USD 79.93 billion by 2032, demonstrating the strong demand for hormone-based treatment options across global healthcare systems. In 2024, North America dominated the market with a 51.71% share, supported by advanced healthcare infrastructure, strong reimbursement policies, and high awareness of early cancer diagnosis.
Hormone therapy remains a cornerstone of prostate cancer management. Also known as Androgen Deprivation Therapy (ADT), this treatment reduces hormone levels that fuel tumor growth and is widely used in metastatic and advanced-stage cancers. With global cancer burden intensifying-GLOBOCAN 2022 recorded 1.47 million prostate cancer cases, making it the 4th most common cancer-there is rising dependence on hormone therapy as a core treatment approach.
Market Drivers
The development of advanced hormonal therapies is a major market driver. Leading pharmaceutical companies are introducing new androgen receptor inhibitors and next-generation GnRH-based therapies to overcome resistance and improve patient outcomes. In November 2023, Astellas Pharma and Pfizer received FDA approval for XTANDI for non-metastatic Castration-Sensitive Prostate Cancer, enabling broader treatment use.
Strong R&D pipelines and increasing clinical trials continue to accelerate therapeutic innovation. The rising global incidence of prostate cancer, coupled with expanding access to advanced therapies in developed nations, also supports continuous market growth.
Market Restraints
A significant restraint is the growing resistance to conventional ADT. Over time, prostate cancer cells may mutate and continue producing androgens, diminishing therapeutic effectiveness. For instance, research in January 2024 by Sylvester Comprehensive Cancer Center revealed that the enzyme 3BHSD1 enables tumors to regenerate androgens even during hormone suppression therapy, accelerating disease progression. This resistance challenges treatment efficacy and limits long-term therapy adoption.
Market Challenges
Patients undergoing hormonal therapy often experience substantial side effects, making treatment adherence challenging. Erectile dysfunction and libido loss are common complications. A study published by Elsevier in 2020 reported that 82% of ADT patients experienced erectile problems, while 64% reported loss of sexual desire, negatively affecting quality of life. Such adverse effects remain a major barrier to therapy continuation.
Market Opportunities
Combination therapies offer significant future opportunities. Pharmaceutical companies are increasingly exploring combinations of PARP inhibitors with ADT to address resistance and extend survival. In February 2025, the TALAPRO-2 trial demonstrated that combining talazoparib (Talzenna) with enzalutamide (Xtandi) provided a 14-month improvement in overall survival for HRR-deficient metastatic prostate cancer patients, with a 38% reduction in mortality risk. These outcomes highlight the strong potential of combination therapy in shaping the future treatment landscape.
Segmentation Overview
By Drug Class
In 2024, GnRH agonists held the leading share due to high effectiveness in testosterone suppression. Regulatory approvals for products like CAMCEVI continue strengthening this segment. GnRH receptor antagonists and androgen receptor inhibitors are expected to grow substantially due to multiple new approvals and expanded clinical indications.
By Disease State
The metastatic castration-resistant prostate cancer (mCRPC) segment dominated in 2024, driven by rising incidence and increased approvals of targeted therapies. The non-metastatic CRPC segment is set for strong growth as companies broaden their indications.
By Route of Administration
The oral segment held the largest share due to ease of administration and growing generic launches, such as Amneal's FDA-approved generic Abiraterone Acetate. The parenteral segment continues to expand with new injectable formulations under trial.
By Distribution Channel
Hospital pharmacies lead due to specialized cancer treatment centers and physician-supervised therapy administration. Retail and online pharmacies are growing steadily due to improved drug accessibility.
Regional Outlook
North America
The market reached USD 8.31 billion in 2024, driven by high prostate cancer incidence and advanced therapeutic adoption. Strong R&D presence and FDA approvals contribute to regional dominance.
Europe
Europe holds the second-largest share, supported by healthcare authority endorsements. In 2024, NICE recommended ORGOVYX as a cost-effective treatment option.
Asia Pacific
Expected to be the fastest-growing region due to rising aging populations and increasing therapy approvals. In July 2024, China's NMPA approved XTANDI for metastatic disease.
Latin America & Middle East/Africa
Moderate growth is expected, driven by rising collaborations and gradual improvements in prostate cancer treatment access.
Conclusion
The global prostate cancer hormone therapy market is on a strong growth trajectory, rising from USD 16.07 billion in 2024 to USD 20.44 billion in 2025, and projected to reach USD 79.93 billion by 2032. With expanding treatment innovations, increasing approvals, and strong R&D momentum, hormone therapy remains central to the future of prostate cancer care.
Segmentation By Drug Class
- Androgen Receptor Inhibitors
- Gonadotropin Releasing Hormone (GnRH) Agonist
- Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- Others
By Route of Administration
- Oral
- Parenteral
By Disease State
- Metastatic Castration-Resistant Prostate Cancer
- Non-Metastatic Castration-Resistant Prostate Cancer
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Region
- North America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
- U.K.
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
- Latin America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
- 4.2. Pipeline Analysis, by Key Players
- 4.3. Overview of Alternative Therapies
- 4.4. Key Start-ups in the Market
- 4.5. New Product Launches, by Key Players
- 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.7. Impact of COVID-19 on the Market
5. Global Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. Androgen Receptor Inhibitors
- 5.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
- 5.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast - By Route of Administration
- 5.2.1. Oral
- 5.2.2. Parenteral
- 5.3. Market Analysis, Insights and Forecast - By Disease State
- 5.3.1. Metastatic Castration-Resistant Prostate Cancer
- 5.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Drug Stores & Retail Pharmacies
- 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. Androgen Receptor Inhibitors
- 6.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
- 6.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 6.1.4. Others
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Oral
- 6.2.2. Parenteral
- 6.3. Market Analysis, Insights and Forecast - By Disease State
- 6.3.1. Metastatic Castration-Resistant Prostate Cancer
- 6.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Drug Stores & Retail Pharmacies
- 6.4.3. Online Pharmacies
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. Androgen Receptor Inhibitors
- 7.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
- 7.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 7.1.4. Others
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.3. Market Analysis, Insights and Forecast - By Disease State
- 7.3.1. Metastatic Castration-Resistant Prostate Cancer
- 7.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Drug Stores & Retail Pharmacies
- 7.4.3. Online Pharmacies
- 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.5.1. Germany
- 7.5.2. U.K.
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. Androgen Receptor Inhibitors
- 8.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
- 8.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 8.1.4. Others
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Oral
- 8.2.2. Parenteral
- 8.3. Market Analysis, Insights and Forecast - By Disease State
- 8.3.1. Metastatic Castration-Resistant Prostate Cancer
- 8.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Drug Stores & Retail Pharmacies
- 8.4.3. Online Pharmacies
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. Androgen Receptor Inhibitors
- 9.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
- 9.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 9.1.4. Others
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.3. Market Analysis, Insights and Forecast - By Disease State
- 9.3.1. Metastatic Castration-Resistant Prostate Cancer
- 9.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital Pharmacies
- 9.4.2. Drug Stores & Retail Pharmacies
- 9.4.3. Online Pharmacies
- 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. Androgen Receptor Inhibitors
- 10.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
- 10.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 10.1.4. Others
- 10.2. Market Analysis, Insights and Forecast - By Route of Administration
- 10.2.1. Oral
- 10.2.2. Parenteral
- 10.3. Market Analysis, Insights and Forecast - By Disease State
- 10.3.1. Metastatic Castration-Resistant Prostate Cancer
- 10.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital Pharmacies
- 10.4.2. Drug Stores & Retail Pharmacies
- 10.4.3. Online Pharmacies
- 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2024)
- 11.2. Company Profiles
- 11.2.1. Astellas Pharma Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Pfizer Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Johnson & Johnson Services, Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Ferring Pharmaceuticals Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. AbbVie Inc.
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. AstraZeneca
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Accord BioPharma, Inc.
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Bayer AG
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.1. Astellas Pharma Inc.
List of Tables
- Table 1: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
- Table 2: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 3: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
- Table 4: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
- Table 5: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Region, 2019-2032
- Table 6: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
- Table 7: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 8: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
- Table 9: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
- Table 10: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country, 2019-2032
- Table 11: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
- Table 12: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 13: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
- Table 14: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
- Table 15: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 16: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
- Table 17: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 18: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
- Table 19: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
- Table 20: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 21: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
- Table 22: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 23: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
- Table 24: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
- Table 25: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 26: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2019-2032
- Table 27: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 28: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2019-2032
- Table 29: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2019-2032
- Table 30: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
List of Figures
- Figure 1: Global Prostate Cancer Hormone Therapy Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
- Figure 2: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024 & 2032
- Figure 3: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024 & 2032
- Figure 4: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024 & 2032
- Figure 5: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024 & 2032
- Figure 6: Global Prostate Cancer Hormone Therapy Market Value (USD billion), by Region, 2024 & 2032
- Figure 7: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
- Figure 8: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
- Figure 9: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 10: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
- Figure 11: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
- Figure 12: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
- Figure 13: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 14: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
- Figure 15: North America Prostate Cancer Hormone Therapy Market Value (USD billion), By Country, 2024 & 2032
- Figure 16: North America Prostate Cancer Hormone Therapy Market Value Share (%), By Country, 2024
- Figure 17: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
- Figure 18: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
- Figure 19: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 20: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
- Figure 21: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
- Figure 22: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
- Figure 23: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 24: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
- Figure 25: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 26: Europe Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2024
- Figure 27: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
- Figure 28: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
- Figure 29: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 30: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
- Figure 31: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
- Figure 32: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
- Figure 33: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion),by Distribution Channel, 2024 & 2032
- Figure 34: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
- Figure 35: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 36: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2024
- Figure 37: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
- Figure 38: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
- Figure 39: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 40: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
- Figure 41: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
- Figure 42: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
- Figure 43: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 44: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
- Figure 45: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 46: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2024
- Figure 47: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2024 & 2032
- Figure 48: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2024
- Figure 49: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 50: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2024
- Figure 51: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2024 & 2032
- Figure 52: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2024
- Figure 53: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 54: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2024
- Figure 55: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 56: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2024
Figure 57: Global Prostate Cancer Hormone Therapy Market Share (%), By Company, 2024
